The drug, a small molecule protein inhibitor, brought in $132 million in the first quarter, missing consensus estimates by 17 ...

GSK’s dealmaking will be “cautious and disciplined” under the current trade war, but the pharma will focus on looking for ...

It’s been a fraught road for the proposed merger between Acelyrin and Alumis, with Tang Capital’s Concentra Biosciences in ...

What a CEO makes can be staggering from the seat of a rank-and-file employee, whose pay is typically in the five-to-six digit ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Policy uncertainties are impacting biopharma dealmaking from continent to continent, with companies being asked to walk a ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

Despite executing "perfectly," Octagon confronted a “scientific no-go,” CEO Isaac Stoner said in his LinkedIn post announcing ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by ...